Primary Job Title Board of Directors Primary Organization 
TNG Pharmaceuticals
Location Birmingham, Alabama, United States Regions Southern US Gender Male
Facebook View on Facebook LinkedIn View on LinkedIn
Kent R. Van Kampen DVM, PhD served as the Chief Operating Officer and Chief Executive Office of Vaxin, Inc. before retiring. Dr. Van Kampen has a wealth of experience in the field of vaccinology especially in the research, development and commercialization of vaccines.
From 1985-91 he served as the Chief Executive Officer of Virogenetics, Troy,
New York, a subsidiary of Institut Merieux, Lyon, France. At Virogenetics, a number of recombinant animal vaccines were designed that are currently marketed by Merial. He was instrumental in obtaining a license from the USDA for Raboral, an orally active rabies vaccine used to vaccinate wildlife.
At ImmunoMed, Inc. Tampa, Florida he helped license one of the first immunomodulators used in large animals. From 1976 to 1980, Dr. Van Kampen served as Head of the Department of Animal, Dairy, and Veterinary Sciences at Utah State University. From 1980 to 1984, he headed of the Physiological Research Laboratory and was Director of The Implantable Drug Delivery Device program forMedtronic, Minneapolis, Minnesota. Dr. Van Kampen serves as the Chairman of the Board of Directors of ImmunoMed Corp and as a Director of Cognitive Engineering, SVK Laboratories, HMV Corp. and The Van Kampen Group Inc.
He also serves as a Member ofthe Scientific Advisory Board at Qu Biologics Inc., Vancouver, BC, Canada Dr. Van Kampen is a Co-editor of a book and the author of more than 70 scientific publications.
In 1994, Dr. Van Kampen was awarded an Honorary Doctorate Degree from Utah State University. He is a Diplomate of the American College of Veterinary Pathologists and holds a Doctorate Degree in Veterinary Medicine from Colorado State University and a Ph.D. in Comparative Pathology from the University of California, Davis.
